AstraZeneca boost as EU approves cancer drug

By EMILY HAWKINS

Updated: 21:50 BST, 4 July 2025

An AstraZeneca cancer drug received the green light by European regulators yesterday.

The London-listed drugs maker revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union.

It comes amid reports that AstraZeneca – the FTSE 100’s largest company – is considering moving its listing from the UK to the US in what would be a hammer blow to London’s stock market. 

The speculation was fuelled by the pharmaceutical sector’s growing frustration with the UK’s rules on approving medicines as well as a row over drug prices between the industry and the NHS.

Boost: AstraZeneca revealed that its bladder cancer treatment Imfinzi has been approved to treat adult patients in the European Union

Dave Fredrickson, head of AstraZeneca’s oncology haematology unit, said: ‘Imfinzi is poised to transform the standard of care for muscle-invasive bladder cancer in Europe.’

AstraZeneca shares edged up 1.3 per cent yesterday.

DIY INVESTING PLATFORMS

AJ Bell

AJ Bell

Easy investing and ready-made portfolios

Hargreaves Lansdown

Hargreaves Lansdown

Free fund dealing and investment ideas

interactive investor

interactive investor

Flat-fee investing from £4.99 per month

InvestEngine

InvestEngine

Account and trading fee-free ETF investing

Trading 212

Trading 212

Free share dealing and no account fee

Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence.

Compare the best investing account for you

:
AstraZeneca boost as EU approves cancer drug

***
Read more at DailyMail.co.uk